Ash 2019 – Roche doesn’t disappoint with bispecific
The first in-depth look Roche’s anti-CD20 bispecific, mosunetuzumab, reveals some very encouraging response rates, even in patients who failed Car-T therapy.
Biogen teases with lupus ahead of aducanumab's big Alzheimer’s reveal
Biogen’s clinical-stage pipeline carries little weight, and encouraging data in lupus is unlikely to change that.
SITC – the morning after the night before
Nextcure’s Society for Immunotherapy of Cancer presentation gave investors little reason for cheer, but there's better news for Pieris, Celyad and Nektar.
Ash 2019 preview – the first winner and losers emerge
Celgene’s registrational Transcend NHL-001 study will be a big story at Ash, but the early focus falls on what has not been presented.
ASN 2019 preview – fears grow that roxadustat could come up short
Fibrogen investors’ nerves jangle as another key cardiovascular safety readout approaches for the anaemia project.
SITC 2019 preview – Pieris joins the quest for a better Herceptin
Any signs of efficacy with PRS-343 could help Pieris claw back some of its recent losses, but Her2 targeting is increasingly competitive.
Triple meeting – Mirati avoids the worst-case scenario
Like AMG 510, MRTX849 yields partial responses in some lung and colorectal tumours, but investors could have expected better.
Triple meeting – targeted focus validates Merus’s change of tack
Merus’s anti-Her2/Her3 bispecific could have a future in a new targeted setting.
EADV 2019 – Pfizer carves out a niche for abrocitinib
One of the company’s Xeljanz follow-ons is slowly emerging from stealth mode in atopic dermatitis.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.